Stay updated with breaking news from சூச்சித்ர எல்லா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
UAE: 18,407 Covid vaccine doses administered in 24 hours msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Covid-19: WHO likely to take decision on emergency use of Covaxin vaccine soon khaleejtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from khaleejtimes.com Daily Mail and Mail on Sunday newspapers.
Covaxin has received emergency use authorizations in 16 countries, Bharat Biotech said. Highlights The vaccine offers 65.2 per cent protection against Delta variant Phase 3 trials were conducted on 130 symptomatic Covid patients New Delhi: Bharat Biotech s Covaxin is overall 77.8 per cent effective against Covid, the vaccine maker said today in a statement, citing the data from the third phase of clinical trials. The data, however, is yet to be peer-reviewed. The vaccine offers 65.2 per cent protection , it said, against the rapidly emerging Delta variant. It was also found to be 93.4 per cent effective against severe symptomatic COVID-19, the company said. Covaxin is a whole virus inactivated vaccine against SARS-CoV2, developed by Bharat Biotech in partnership with ICMR and NIV Pune. ....
Jul 03,2021 09:08 న్యూఢిల్లీ : కరోనా వైరస్పై కోవాగ్జిన్ మొత్తంగా 77.8 శాతం సమర్థవంతంగా పనిచేస్తుందని వ్యాక్సిన్ తయారీ సంస్థ భారత బయోటెక్ శనివారం తెలిపింది. ఈ మేరకు మూడవ దశ క్లినికల్ ట్రయల్స్ వివరాలను వెల్లడించింది. అయిన్పటికీ ఈ డేటాను ఇంక సమగ్రంగా సమీక్షించాల్సి ఉంది. అదేవిధంగా భారత్లో వెలుగుచూసి.. బెంబేలెత్తిస్తున్న డెల్టా వేరియంట్ నుండి ఈ వ్యాక్సిన్ 65.2 శాతం రక్షణ క� ....
Final Phase-3 results of Covaxin show efficacy of 77.8% against Covid By IANS | 93 Views Final Phase-3 results of Covaxin show efficacy of 77.8% against Covid. Image Source: IANS News New Delhi, July 3 : Efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group. Bharat Biotech has concluded final analysis for Covaxin efficacy from Phase 3 clinical trials. Efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19. Safety analysis demonstrates adverse events reported were similar to placebo, with 12 per cent of subjects experiencing commonly known side effects and less than 0.5 per cent of subjects feeling serious adverse events. ....